Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings, Inc. (NYSE American: INFU) announced a national distribution agreement with Genadyne Biotechnologies, enhancing its portfolio in negative pressure wound therapy (NPWT). InfuSystem will distribute Genadyne’s complete line of wound care products, including the advanced XLR8 Plus NPWT Pump and XLR8 Dressing Kit with Silver. This partnership aims to address supply chain challenges and provide diverse wound care solutions, ultimately improving patient outcomes and reducing healthcare costs. InfuSystem emphasizes its commitment to facilitating outpatient care and enhancing service delivery in the durable medical equipment sector.

InfuSystem Holdings, Inc. (NYSE American: INFU) reported record net revenues of $109.9 million for 2022, marking a 7% increase from 2021. The fourth quarter net revenues reached $28.8 million, a 9% year-over-year increase. Key segments include Integrated Therapy Services (ITS) with $68.9 million and Durable Medical Equipment (DME) at $41.0 million, growing 5% and 12% respectively. Adjusted EBITDA for 2022 was $20.7 million, down 14%. The company projects 2023 revenue growth of 8% to 10% with an Adjusted EBITDA margin over 19%. Management remains optimistic about strategic partnerships and growth in pain management services.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced it will release preliminary fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. A conference call will be held on the same day at 9:00 a.m. Eastern Time to discuss these results. The company operates through two platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services), providing comprehensive outpatient care. InfuSystem ensures local client support through its Centers of Excellence across several states and Ontario, Canada, enhancing its service delivery and operational efficiencies.

InfuSystem Holdings, Inc. (NYSE American: INFU), a key provider of outpatient care for durable medical equipment, will participate in Craig-Hallum’s 13th Annual Alpha Select Conference on November 17, 2022, at the Sheraton New York Times Square. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will be present for one-on-one meetings. InfuSystem operates under two platforms: Integrated Therapy Services and Durable Medical Equipment Services, serving various healthcare needs across the U.S. and Canada.

InfuSystem Holdings reported record net revenues of $27.3 million for Q3 2022, up 3% year-over-year, with Integrated Therapy Services (ITS) revenues rising to $17.4 million, a 5% increase. Operating income increased by $1.3 million to $0.9 million, with net income of $0.4 million or $0.02 per diluted share. Gross profit also rose to $16.2 million, marking a 6% increase. The company projects full-year revenue at about $112 million, on the lower end of growth guidance of 10% to 13%.